---
layout: post
title: "Ocugen(OCGN.US)盘前暴跌近30% 新冠疫苗EUA申请遭FDA拒绝"
date: 2022-03-04 20:28:18 +0800
categories: zhitongcaijingwang
tags: 智通财经网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/105.OCGN" data-code="OCGN|105|7" data-code2="OCGN|105|1|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.OCGN&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 OCGN_0" data-code="K OCGN|105|7" data-code2="K OCGN|105|1|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>3月4日(周五)美股盘前，截至发稿，Ocugen(OCGN.US)跌29.48%，报2.32美元。Ocugen在一份声明中表示，美国食品药品监督管理局(FDA)目前拒绝签发新冠疫苗Covaxin用于2至18岁个体的紧急使用授权(EUA)申请。Ocugen计划继续与FDA合作，评估儿童使用COVAXIN的监管途径。<br /></p><p class="em_media">（文章来源：智通财经网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203042297566053>

[返回智通财经网新闻](//finews.withounder.com/category/zhitongcaijingwang.html)｜[返回首页](//finews.withounder.com/)